MDCO News and Press, The Medicines Company From 12/03/19

Shares of The Medicines Company (NASDAQ: MDCO) , a post-commercial biotech, soared 60.4% in November, according to data from S&P Global Market Intelligence . Encouraging pivotal trial results last month inspired Novartis (NYSE: NVS) to make a buyout offer for The Medicines Company fo...

Swiss drugmaker Novartis 's  (NYSE: NVS) $9.7 billion takeover of The Medicines Company (NASDAQ: MDCO) gives the former ownership of an investigational cardiovascular drug called inclisiran. And that may mean trouble for Amgen (NASDAQ: AMGN) and its heart drug Repatha, which ...

3 Penny Stocks To Watch As 2019 Comes To End Some penny stocks can often hit new highs seemingly out of nowhere. But it’s important to note that the tell-tale signs could already be in play before the big move even begins. When it comes to identifying some of the top penny stocks to...

Novartis ( NVS ) announced that it would acquire The Medicines Company ( MDCO ) for $9.7 billion. This buyout was at $85 per share which was a 25% premium to the closing price on Friday. This acquisition comes at the most opportunistic time in that an NDA filing for inclisiran is expecte...

November 26, 2019 Palm Beach, FL –November 26, 2019 – Worldwide, cancer drug sales bring in the most revenues for pharmaceutical companies. Worldwide cancer drug sales are already way ahead of those of other drugs and the revenue generated by them is expected to grow eve...

Although I hadn’t planned writing two articles on Alnylam Pharmaceuticals ( ALNY ) in close succession, the early approval of Givlaari and the subsequent R&D meeting both argued for a write-up, as both are significant to the long-term investment story. Alnylam’s Nov 22 ...

After a brief lull in pharma industry merger and acquisition activity in recent months, two announcements today have broken the silence. Novartis offered to gobble up The Medicines Compan y (NASDAQ: MDCO) for $9.7 billion in total consideration. Shares of the acquisition target have explo...

It turns out the rumors were true. Novartis (NYSE: NVS) is buying The Medicines Company (NASDAQ: MDCO) for $85 per share. That's a 45% premium above the closing price prior to the acquisition rumor being published. Investors kicking themselves for not seeing the higher potential valu...

Gainers:  JanOne (NASDAQ: JAN ) +103% . More news on: JanOne Inc., Sorrento Therapeutics, Inc., The Peck Company Holdings, Inc., Stocks on the move, Read more ...

News Items That are Positive for Markets Ironically, two interesting items come from Bloomberg Media, and then additional news that Mike Bloomberg is running is cheering the market. Firstly, items out of China; "China said it will raise penalties on violations of intellectual property rig...